4/28/2020 1:15:26 AM
PTC Therapeutics Reports Positive Results From Part 2 Of The Pivotal FIREFISH Study Evaluating Risdiplam
4/17/2020 8:04:33 AM
PTC Therapeutics Names Matthew Klein Chief Development Officer And Eric Pauwels To Chief Business Officer
3/16/2020 8:19:05 AM
PTC Therapeutics COO Marcio Souza Resigns
3/2/2020 4:03:22 PM
PTC Therapeutics Q4 Loss/share $1.37 Vs. Loss $0.96 Year Ago
2/6/2020 5:03:13 AM
PTC Therapeutics Presents Positive 1 Year Clinical Data From Part 2 Of The Pivotal SUNFISH Study Of Risdiplam
2/3/2020 8:10:46 AM
PTC Data Shows Translarnaä Preserves Ability To Walk For Longer In Children With Duchenne Muscular Dystrophy
1/23/2020 1:03:07 AM
PTC Therapeutics Says FIREFISH Study Meets Primary Endpoint In Patients Living With Type 1 SMA
11/25/2019 1:32:18 AM
PTC Therapeutics: FDA Granted Priority Review For NDA For Risdiplam For Spinal Muscular Atrophy Treatment
11/11/2019 1:12:08 AM
PTC Therapeutics Says Risdiplam Pivotal SUNFISH Study Meets Primary Endpoint
10/24/2019 8:25:22 AM
PTC Therapeutics Announces Results From Long-Term AADC Deficiency Gene Therapy Treatment For Sustained Improvements
10/7/2019 8:02:57 AM
PTC Establishes Strategic Collaboration With Aldevron To Support GMP Plasmid Manufacturing
9/18/2019 8:28:55 AM
PTC Therapeutics Prices Private Offering Of $250.0 Mln Of Its Convertible Senior Notes Due 2026
9/18/2019 8:28:29 AM
PTC Therapeutics Prices Public Offering Of 2.48 Mln Shares At $40.40 Per Share
9/17/2019 4:03:52 PM
PTC Therapeutics Announces Proposed Public Offering Of Common Stock
8/6/2019 4:39:11 PM
PTC Therapeutics Q2 Loss/share $0.75 Vs. Loss $0.21 Year Ago